Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | PBK | Q96KB5 | 4/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21225620 | 1.00 | SYK (0.43) | SYKMLLT1DRD4PBKSMYD3 | |
| SCHEMBL21225618 | 1.00 | SYK (0.43) | SYKMLLT1DRD4PBKSMYD3 | |
| SCHEMBL21225769 | 0.93 | SYK (0.49) | SYKMLLT1PBK | |
| SCHEMBL21225377 | 0.93 | SYK (0.49) | SYKMLLT1PBK | |
| SCHEMBL21225379 | 0.93 | SYK (0.49) | SYKMLLT1PBK | |
| SCHEMBL21225682 | 0.90 | MLLT1 (0.41) | SYKMLLT1SMYD3HPGD | |
| SCHEMBL29990642 | 0.90 | MLLT1 (0.41) | SYKMLLT1SMYD3HPGD | |
| SCHEMBL25531884 | 0.90 | SYK (0.41) | SYKMLLT1DRD4PBKSMYD3 | |
| SCHEMBL25531945 | 0.90 | SYK (0.41) | SYKMLLT1DRD4PBKSMYD3 | |
| SCHEMBL25532031 | 0.86 | SMYD3 (0.45) | SYKMLLT1PBKSMYD3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018033-B2 | Inhibitors of protein arginine deiminases | FORWARD THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | claimed |
| US-11453676-B2 | Inhibitors of protein arginine deiminases | FORWARD THERAPEUTICS, INC. (US) | 2022-09-27 | — | — | US | claimed |
| US-20210053975-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2021-02-25 | — | — | US | claimed |
| EP-3746430-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | Padforward LLC (US) | 2020-12-09 | — | — | EP | claimed |
| WO-2019152883-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | PADFORWARD LLC (US) | 2019-08-08 | — | — | WO | claimed |
| US-12018033-B2 | Inhibitors of protein arginine deiminases | FORWARD THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230151018-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151018-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11453676-B2 | Inhibitors of protein arginine deiminases | FORWARD THERAPEUTICS, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20210053975-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210053975-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| EP-3746430-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | Padforward LLC (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019152883-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | PADFORWARD LLC (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152883-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | PADFORWARD LLC (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151018-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | PADI2, PADI1, PADI4 | SYK 2709/4885MLLT1 858/4885DRD4 4836/4885 |
| US-11453676-B2 | Inhibitors of protein arginine deiminases | PADI2, PADI1, PADI4 | SYK 2693/4885MLLT1 987/4885DRD4 4837/4885 |
| US-20210053975-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | PADI2, PADI1, PADI4 | SYK 2709/4885MLLT1 858/4885DRD4 4836/4885 |
| US-12018033-B2 | Inhibitors of protein arginine deiminases | PADI2, PADI1, PADI4 | SYK 2547/4885MLLT1 1129/4885DRD4 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.